Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience

Bone Marrow Transplantation volume 43, pages 423–427 (2009)Cite this article

Abstract

GVHD remains a serious complication after allogeneic SCT. We describe 13 paediatric patients treated with daclizumab for refractory acute GVHD (aGVHD). After 30 days of daclizumab administration, all patients with cutaneous aGVHD reached complete response. Among patients with gastrointestinal disease, 50 and 30% had complete and partial response, respectively, whereas 11 and 55% of patients with hepatic aGVHD achieved CR and PR, respectively. Overall, complete (46%) and partial (46%) responses were demonstrated in 92% of our patients, whereas the remaining patients (8%) were nonresponders. No life-threatening infectious episodes were recorded within 100 days from transplant in this selected group of paediatric patients. Overall 46% of patients were alive at a median of 461 days from SCT, but 50% of them developed chronic GVHD. In our experience, daclizumab proved to be a useful and safe treatment for refractory and steroid-resistant/dependent aGVHD, in particular for cutaneous and low-moderate intestinal involvement.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ferrara JL, Yanik G . Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies. Clin Adv Hematol Oncol 2005; 3: 415–419, 428.

    PubMed  Google Scholar 

  2. Bacigalupo A . Management of acute graft-versus-host disease. Br J Haematol 2007; 137: 87–98.

    Article  CAS  PubMed  Google Scholar 

  3. Deeg J . How I treat refractory acute GvHD. Blood 2007; 109: 4119–4126; review.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Morris ES, Hill GR . Advances in the understanding of acute graft-versus-host disease. Br J Haematol 2007; 137: 3–19.

    Article  CAS  PubMed  Google Scholar 

  5. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83–89.

    CAS  PubMed  Google Scholar 

  6. Willenbacher W, Basara N, Blaw IW, Fauser AA, Kiehl MG . Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 820–823.

    Article  CAS  PubMed  Google Scholar 

  7. Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi T, Kleiner D et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004; 124: 777–786.

    Article  CAS  PubMed  Google Scholar 

  8. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J et al. Treatment of steroid-resistant acute graft versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35: 1003–1010.

    Article  CAS  PubMed  Google Scholar 

  9. Perales MA, N Ishill, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H et al. Long-term follow up of patients treated with daclizumab for steroid-refractory acute graft-vs-host-disease. Bone Marrow Transplant 2007; 40: 481–486.

    Article  CAS  PubMed  Google Scholar 

  10. Bordigoni P, Dimicoli S, Clement L, Baumann C, Salmon A, Witz F et al. Daclizumab, an efficient treatment for steroid-refractory acute-versus-host disease. Br J Haematol 2006; 135: 382–385.

    Article  CAS  PubMed  Google Scholar 

  11. Swiatecka-Urban A . Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Paediatr Drugs 2003; 5: 699–716.

    Article  PubMed  Google Scholar 

  12. van Mourik ID, Kelly DA . Immunosuppressive drugs in paediatric liver transplantation. Paediatr Drugs 2001; 3: 43–60.

    Article  CAS  PubMed  Google Scholar 

  13. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  14. Tachey DT, Bickert B, Bunin N . Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant 2006; 37: 95–99.

    Article  Google Scholar 

  15. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104: 1559–1564.

    Article  CAS  PubMed  Google Scholar 

  16. Anasetti C, Hansen JA, Waldman TA, Appelbaum FR, Davis J, Deeg HJ et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320–1327.

    CAS  PubMed  Google Scholar 

  17. Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118–127.

    Article  CAS  PubMed  Google Scholar 

  18. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111: 2470–2475.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported in part by the Italian Ministry of Health, Programma di Ricerca Finalizzata ex articolo 12 D.L.gs 502/92 2005 Assistenza Domiciliare in Bambini ed Adulti affetti da Patologie Emato-Oncologiche.

Author information

Authors and Affiliations

  1. Department of Paediatric Haematology/Oncology, Stem Cell Transplant Unit, G Gaslini Research Institute, Genoa, Italy

    M Miano, D Cuzzubbo, P Terranova, S Giardino, E Lanino, G Morreale, G Dini & M Faraci

  2. Department of Paediatric Haematology/Oncology, Infectious Disease Unit, G Gaslini Research Institute, Genoa, Italy

    E Castagnola

Authors
  1. M Miano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Cuzzubbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Terranova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Giardino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Lanino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Morreale
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Castagnola
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Dini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Faraci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Faraci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miano, M., Cuzzubbo, D., Terranova, P. et al. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience. Bone Marrow Transplant 43, 423–427 (2009). https://doi.org/10.1038/bmt.2008.331

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.331

Keywords

This article is cited by

Search

Advanced search

Quick links